Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
05/2012
05/31/2012US20120135001 Combination of anti-ctla4 antibody with dasatinib for the treatment of proliferative diseases
05/31/2012US20120135000 Methods and compositions for treating ocular disorders
05/31/2012US20120134999 PORIN B (PorB) AS A THERAPEUTIC TARGET FOR PREVENTION AND TREATMENT OF INFECTION BY CHLAMYDIA
05/31/2012US20120134998 Secreted ap2 and methods of inhibiting same
05/31/2012US20120134997 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
05/31/2012US20120134996 Anti-met monoclonal antibody, fragments and vectors thereof , for the treatment of tumors and corresponding products
05/31/2012US20120134995 Method for predicting the therapeutic responseiveness of a patient to a medical treatment with an egfr inhibitor
05/31/2012US20120134994 Monoclonal antibodies to fibroblast growth factor receptor 2
05/31/2012US20120134993 Compositions and methods for using multispecific-binding proteins comprising an antibody-receptor combination
05/31/2012US20120134992 Mesothelin antibody protein fusions and methods of use
05/31/2012US20120134991 Compositions and methods for modulating d1-d2 dopamine receptor interaction and function
05/31/2012US20120134990 Combination therapy with type i and type ii anti-cd20 antibodies
05/31/2012US20120134989 Antibody formulations
05/31/2012US20120134988 Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
05/31/2012US20120134987 Kinase inhibitors and methods of their use
05/31/2012US20120134986 Methods of Prognosis for Non-Hodgkin Lymphoma
05/31/2012US20120134985 Methods for modulating metabolic and circadian rhythms
05/31/2012US20120134984 Molecules with extended half-lives and uses thereof
05/31/2012US20120134983 Method for Identifying Interventions that Control the Translational Activity of Ribosomal Proteins in Different MRNA Expression
05/31/2012US20120134982 Polypeptides, antibody variable domains & antagonists
05/31/2012US20120134981 Genes linking several complications of type-2 diabetes (t2d)
05/31/2012US20120134959 Pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
05/31/2012US20120134957 Latent phase viral interleukin-10-(vii-10) and uses thereof
05/31/2012US20120134956 Colloidal metal compositions and methods
05/31/2012US20120134955 Pyrimidopyrimidoindazole derivative
05/31/2012US20120134954 Defensin-antigen fusion proteins
05/31/2012US20120134927 Beta cell marker antibody
05/31/2012US20120134925 Application and Uses of PRG4 and Therapeutic Modulation Thereof
05/31/2012US20120132204 Unit dose dry powder inhaler
05/31/2012CA2856565A1 Compositions and methods
05/31/2012CA2818892A1 Adjuvant
05/31/2012CA2818827A1 Compositions and methods for treatment in broad-spectrum, undifferentiated or mixed clinical applications
05/31/2012CA2818814A1 Anti-il-6 antibodies for the treatment of anemia
05/31/2012CA2818813A1 Anti-il-6 antibodies for the treatment of oral mucositis
05/31/2012CA2818738A1 Biomarkers for predicting the efficacy of an immunotherapy against cancer
05/31/2012CA2818712A1 Compositions and methods for treating or preventing lupus
05/31/2012CA2818684A1 Nk cell modulating treatments and methods for treatment of hematological malignancies
05/31/2012CA2817415A1 Antibodies that bind notum pectinacetylesterase
05/30/2012EP2458013A1 Anti alpha v beta 6 antibodies and uses therof
05/30/2012EP2458012A1 Anti alpha v beta 6 antibodies and uses thereof
05/30/2012EP2458003A1 Attenuated chimeric flavivirus bearing attenuated jamanese encephalitis virus gene as backbone
05/30/2012EP2457928A2 Monoclonal human tumor-specific antibody
05/30/2012EP2457926A1 Novel method for preventing or treating m tuberculosis infection
05/30/2012EP2457589A1 Reverse targeting lipid vesicle
05/30/2012EP2457587A1 Anitbodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
05/30/2012EP2457586A1 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
05/30/2012EP2457585A1 Methods for treating conditions associated with MASP-2 dependent complement activation
05/30/2012EP2457584A1 Myxoma virus mutants for cancer treatment
05/30/2012EP2457583A1 Nucleic acids encoding PRRSV GP5-ecto and M protein
05/30/2012EP2457577A1 Diphtheria toxin variant
05/30/2012EP2457096A2 Phenotyping tumor-infiltrating leukocytes
05/30/2012EP2456790A1 Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
05/30/2012EP2456464A1 Methods of treating her2 positive cancer with her2 receptor antagonist in combination with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin
05/30/2012EP2456463A1 Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast
05/30/2012EP2456462A2 Vaccine for the prevention of acute lymphoblastic leukemia
05/30/2012EP2456461A1 Enzymatic composition for the digestion of chicken embryos
05/30/2012EP2456460A1 Methods and compositions for treating and preventing disease associated with avb5 integrin
05/30/2012EP2456459A1 Vaccine
05/30/2012EP2456458A2 Dendritic cell vaccines for asparaginyl- - hydroxylase expressing tumors
05/30/2012EP2324112B1 Mutant pestivirus with mutations in core gene and ns3 region
05/30/2012EP2097102B1 Combination vaccine having reduced polio virus antigen quantities
05/30/2012EP2078531B1 Pharmaceutical compositions and methods useful for modulating angiogenesis
05/30/2012EP2064224B1 Tissue culture system for production of hepatitis c virus
05/30/2012EP2027150B1 Allorestricted peptide-specific t cells
05/30/2012EP1946769B1 Multivalent vaccine composition with reduced dose of Haemophilus influenzae type B
05/30/2012EP1601376B1 Use of myxoma virus for therapeutic treatment of cancer and chronic viral infection
05/30/2012EP1575516B1 Chimeric and humanized antibodies to alpha5 beta1 integrin that modulate angiogenesis
05/30/2012EP1355673B1 Multivalent meningococcal polysaccharide-protein conjugate vaccine
05/30/2012EP1283057B2 Cell proliferation inhibitors
05/30/2012EP1176193B1 Inhibitors for viral infection targeting integrase n-terminal region
05/30/2012CN1997386B Methods of treating type I diabetes by blocking VEGF-mediated activity
05/30/2012CN1985000B T-cell death-inducing epitopes
05/30/2012CN1942161B Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
05/30/2012CN1901930B Integrin alphaiibbeta3 specific antibodies and peptides
05/30/2012CN1860130B New soluble and stabilized trimeric form of GP41 polypeptides
05/30/2012CN1852976B Binding constructs and methods for use thereof
05/30/2012CN1852730B Modulators of P-selectin glycoprotein ligand 1
05/30/2012CN1798766B Humanized antibodies that recognize beta amyloid peptide
05/30/2012CN1703238B Recombinant intracellular pathogen immunogenic compositions and methods for use
05/30/2012CN102483414A 作为肝癌诊断标记和治疗靶标的钙黏着蛋白-17 As a diagnostic marker of liver cancer and a therapeutic target cadherin -17
05/30/2012CN102482647A Production of polio virus at high titers for vaccine production
05/30/2012CN102482646A 幽门螺杆菌脂多糖外部核心表位 Helicobacter pylori lipopolysaccharide external core epitope
05/30/2012CN102482357A Humanized anti-cdcp1 antibodies
05/30/2012CN102482356A 针对toll样受体2的人源化的抗体及其用途 For toll-like receptor 2 humanized antibodies and uses thereof
05/30/2012CN102482352A Antibodies against il-17br
05/30/2012CN102482351A Anti-c[epsilon]mx antibodies capable of binding to human mige on b lymphocytes
05/30/2012CN102482349A 抗vegf抗体和其用途 Anti-vegf antibodies and their use
05/30/2012CN102482347A Modified antibody compositions, and methods of making and using thereof
05/30/2012CN102482344A 速度因子 Speed ​​Factor
05/30/2012CN102482328A 包含血凝素的嵌合流感病毒样颗粒 Chimeric influenza virus-like particles containing the hemagglutinin
05/30/2012CN102482327A 脂质化肿瘤相关抗原及其免疫治疗的组成物及方法 Its lipid-based tumor associated antigen immunotherapy composition and method
05/30/2012CN102481376A Immunomodulatory agent-polymeric compounds
05/30/2012CN102481375A Nanocarriers possessing components with different rates of release
05/30/2012CN102481374A Nanocarriers possessing components with different rates of release
05/30/2012CN102481371A 用于治疗家禽的粘性软质凝胶 For the treatment of poultry sticky soft gel
05/30/2012CN102481367A Bi-specific digoxigenin binding antibodies
05/30/2012CN102481366A 用于治疗癌症的针对cdcp1的抗体 For the treatment of cancer, an antibody against cdcp1
05/30/2012CN102481365A Method of treating cancer with dll4 antagonist and chemotherapeutic agent
05/30/2012CN102481364A 用her2受体拮抗剂联合7-乙基-10-羟基喜树碱的多臂聚合缀合物治疗her2阳性癌症的方法 Conjugates for cancer therapy her2 positive her2 receptor antagonist combined with 7-ethyl-10-hydroxycamptothecin dobby polymerization
05/30/2012CN102481363A 含有抗癌特异性膜抗原的抗体的癌治疗剂 Anti-cancer therapeutic agent for cancer comprising the antibody specific membrane antigen
1 ... 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 ... 1823